- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04179435
Kognitiv og hjerneutvikling hos ungdom med Gilles de la Tourettes syndrom (CADETS)
Utvikling Cognitif et cérébral Chez Les Adolescents Souffrants d'un Syndrome de Gilles de la Tourette
In children with neurodevelopmental disorders, adolescence is usually associated with a reshaping of the clinical picture and symptomatology. Tourette syndrome (TS) is a paradigmal neurodevelopmental syndrome characterised by involuntary paroxysmal movements (motor tics) and vocalisation (vocal tics) often associated with various psychiatric disorders. The neuronal and cognitive mechanisms associated with TS symptoms improvement during adolescence, or the persistence in adulthood remains unknown, and this is what we aim to address in this study.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Thus, the aims of the present project is threefold:
Aim 1: To evaluate the maturation of cognitive functions in adolescents with TS compared to typically developing adolescents.
To achieve this aim, three distinct cognitive dimensions will be assessed in all subjects (patients and controls): (i) reward sensitivity and habit formation; (ii) cognitive impulsivity and action control and (iii) self-agency.
Aim 2: To identify neuronal correlates of cognitive function and brain development in health and disease. To achieve this aim, we will use a combined behavioural (as described in Aim 1), (i) neuroimaging and (ii) TMS approaches.
Aim 3: To predict clinical outcome . In this part of the project we aim to identify behavioural, imaging or neurophysiological markers of clinical outcome in patients with TS.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Paris, Frankrike, 75013
- Hôpital de la Pitié-Salpêtrière
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Tourette syndrome
- Ages 13 - 18
- Acceptance to perform the Brain MRI
- Acceptance to perform the cognitive testing
- Acceptance to perform the TMS measures
Exclusion Criteria:
- Learning disability
- Incompatibility with MRI procedure (metal body implants, pregnancy)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Tourette syndrome
Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures |
Testing on cognitive computerized tasks Brain MRI scans Measure of the cortical inhibitory capacity using TMS measures |
|
Annen: Controls
Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures |
Testing on cognitive computerized tasks Brain MRI scans Measure of the cortical inhibitory capacity using TMS measures |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Behavioral test main outcome measures [1]
Tidsramme: from 16 to 20 months
|
reaction times |
from 16 to 20 months
|
|
Behavioral test main outcome measures [2]
Tidsramme: from 16 to 20 months
|
discounting factor |
from 16 to 20 months
|
|
Behavioral test main outcome measures [3]
Tidsramme: from 16 to 20 months
|
number of premature responses |
from 16 to 20 months
|
|
Behavioral test main outcome measures [4]
Tidsramme: from 16 to 20 months
|
agency composite scores |
from 16 to 20 months
|
|
Brain MRI scan measures
Tidsramme: from 16 to 20 months
|
whole brain structural connectivity, whole brain functional connectivity, brain cortical and subcortical structures volumes and morphology |
from 16 to 20 months
|
|
Transcranial magnetic stimulation
Tidsramme: from 16 to 20 months
|
Short Intracortical Inhibition (SICI) scores |
from 16 to 20 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Worbe Yulia, MD, PhD, Institut National de la Santé Et de la Recherche Médicale, France
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- C19-11
- 2019-A00992-55 (Registeridentifikator: CADETS)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .